Back to 2016 Annual Meeting Posters

Background: Off label parallel endografting has been increasingly criticized in favor of on-label custom fenestrated endografts. There remain limited direct comparisons, however, between concurrent patient populations treated by similarly experienced operators. Hence, we seek to evaluate the relative efficacy of the two techniques in treating complex aortic pathology.
Methods: All patients treated by parallel endografting (PE) or with Cook Zenith Fenestrated (Zfen) devices from January 2010 to June 2015 were reviewed, excluding those treated for rupture. Patients were all evaluated for open repair as well as for fenestrated devices since its availability at our center in July 2013. Patients predating fenestrated access or not meeting anatomic IFU criteria and preferring endovascular therapy were treated with parallel endografting.
Results: A total of 103 patients were treated during the period reviewed, 64 (62.1%) by PE and 39 (37.9%) with Zfen. The two procedures required similar length of surgery (243 minutes PE vs. 239 minutes Zfen) and contrast volume (112cc PE vs 133cc Zfen). PE, however, was associated with greater length of stay (10.5 vs 6.5 days) and blood loss (680cc vs 409cc), while requiring less fluoroscopy time (52.8 vs 64.6 minutes). At mean 202 days follow up, Zfen have required three reinterventions (2 type III endoleaks and 1 SMA stenosis causing mesenteric ischemia) and there have been zero branch vessels lost. At mean 387 days follow up, PE patients experienced 5 stent occlusions (two repaired endovascularly) and required 9 additional interventions (2 type I endoleaks, 3 type II endoleaks with sac growth, 3 type III endoleaks, and 1 graft infection). Reintervention rates for PE and Zfen were 15.5% and 7.7% respectively, with branch patency rates of 96% and 97%.
Conclusions: Parallel endografting is associated with increased blood loss, length of stay, and rate of reintervention compared to the Zenith fenestrated device. However, it is associated with reduced fluoroscopy time and still maintains similarly high branch patency.